Treatment of medication overuse headache-A review.

adverse effects detoxification programs medication overuse headache neuropharmacology prophylactic headache medication treatment

Journal

Acta neurologica Scandinavica
ISSN: 1600-0404
Titre abrégé: Acta Neurol Scand
Pays: Denmark
ID NLM: 0370336

Informations de publication

Date de publication:
May 2019
Historique:
received: 25 03 2018
revised: 10 01 2019
accepted: 29 01 2019
pubmed: 3 2 2019
medline: 24 5 2019
entrez: 3 2 2019
Statut: ppublish

Résumé

Medication overuse headache (MOH) is the most prevalent chronic headache disorder with a prevalence between 1% and 2% worldwide. The disease has been acknowledged for almost 30 years, yet experts still disagree on how best to treat MOH. By performing a search in PubMed on the terms "medication overuse headache," "analgesics abuse headache," "rebound headache," "drug induced headache," and "headache AND drug misuse" limited to human studies published in English between January 1, 2004, and November 1, 2017, we aimed to evaluate current literature concerning predictors of treatment outcome, inpatient and outpatient treatment programs, initial versus latent administration of prophylactic medications, and to review the effect of prophylactic medications. Selection criteria were prospective, comparative, or controlled trials on treatment of MOH in persons of at least 18 years of age. Several studies evaluated risk factors to predict the outcome of MOH treatment, but many studies were underpowered. Psychiatric comorbidity, high dependence score, and overuse of barbiturates, benzodiazepines, and opioids predicted a poorer outcome of withdrawal therapy. Patients with these risk factors benefit from inpatient treatment, whereas patients without risk factors benefit equally from inpatient and outpatient treatment. Some medications for migraine prophylactics have shown better effect on MOH compared with placebo, but not when combined with withdrawal. We conclude that detoxification programs are of great importance in MOH treatment. Latent administration of prophylactic medications reduces the number of patients needing prophylactic medication. Individualizing treatment according to the predictors of outcome may improve treatment outcome and thus reduce work-related and treatment-related costs.

Identifiants

pubmed: 30710346
doi: 10.1111/ane.13074
doi:

Substances chimiques

Analgesics 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

405-414

Informations de copyright

© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Auteurs

Signe B Munksgaard (SB)

Danish Headache Center, Department of Neurology, Rigshospitalet-Glostrup, Glostrup, Denmark.
Neurovascular Center, Department of Neurology, Zealand University Hospital, Roskilde, Denmark.

Samuel K Madsen (SK)

Danish Headache Center, Department of Neurology, Rigshospitalet-Glostrup, Glostrup, Denmark.
Neurovascular Center, Department of Neurology, Zealand University Hospital, Roskilde, Denmark.

Troels Wienecke (T)

Danish Headache Center, Department of Neurology, Rigshospitalet-Glostrup, Glostrup, Denmark.
Neurovascular Center, Department of Neurology, Zealand University Hospital, Roskilde, Denmark.
Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH